Rifaximin therapy for patients with irritable bowel syndrome without constipation.

@article{Pimentel2011RifaximinTF,
  title={Rifaximin therapy for patients with irritable bowel syndrome without constipation.},
  author={Mark Pimentel and Anthony J Lembo and William D. Chey and Salam F. Zakko and Yehuda Ringel and Jing Yu and Shadreck M. Mareya and Audrey L. Shaw and Enoch Bortey and William P. Forbes},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 1},
  pages={
          22-32
        }
}
BACKGROUND Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an… 

Figures and Tables from this paper

Non-Absorbed Antibiotic for Irritable Bowel Syndrome
  • B. Cash
  • Medicine
    Current gastroenterology reports
  • 2011
TLDR
This report represents pooled data from two identical phase 3, double-blind, placebo-controlled, multicenter trials in which patients with non-constipated IBS were randomized to receive rifaximin or placebo three times a day for 2 weeks.
The role of rifaximin therapy in patients with irritable bowel syndrome without constipation
TLDR
A 2-week course of rifaximin provided significant relief of IBS symptoms, as well as bloating and abdominal pain, and the drug was well tolerated.
Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome
TLDR
Rifaximin plus neomycin is superior to neomyin alone in improving multiple C-IBS symptoms and this effect is predicted by a reduction in breath methane.
Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
TLDR
In a phase 3 study of patients with relapsing symptoms of IBS-D, repeat rifaximin treatment was efficacious and well tolerated and significant improvements were noted for prevention of recurrence, durable response, and bowel movement urgency.
Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?
TLDR
The TARGET-3 has demonstrated that re-treatment is effective in IBS patients who initially respond to rifaximin and experience relapsing symptoms, which is a crucial issue when an antibiotic is used in clinical practice, as the development of mechanisms of resistance among bacteria may affect clinical efficacy.
Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
TLDR
Eluxadoline is a new therapeutic agent that reduced symptoms of IBS with diarrhea in men and women, with sustained efficacy over 6 months in patients who received the 100-mg dose twice daily.
Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
TLDR
Rifaximin is efficacious in improving abdominal pain in adults with IBS-D and should be considered as a first-line treatment for IBS with diarrhea, according to need.
Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome
TLDR
Oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints and ‘Intestinal hyperpermeability’ (elevated urinary lactulose/mannitol ratios) was normalised in the glutamine but not the control group.
Rifaximin Therapy in Patients of Irritable Bowel Syndrome Without Constipation Randomized Controlled Trial
TLDR
Prescribing rifaximin should be considered in treatment of IBS patients as it provides a promising treatment option which is cost effective and has fewer side effects.
Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use
TLDR
Current data showing the association of small intestinal bacterial overgrowth (SIBO) and IBS is explored as well as the available data on the clinical use of rifaximin in the treatment of SIBO in patients with IBS.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome
TLDR
Whether the nonabsorbed antibiotic rifaximin is more effective than placebo in reducing symptoms in adults with IBS is determined.
Review of rifaximin as treatment for SIBO and IBS.
  • M. Pimentel
  • Medicine
    Expert opinion on investigational drugs
  • 2009
TLDR
Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.
A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence
TLDR
Rifaximin is a safe and effective treatment for abdominal bloating and flatulence, including in IBS patients, and symptom improvement correlates with reduction in H2-breath excretion.
Normalization of Lactulose Breath Testing Correlates With Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study
TLDR
Normalization of LBT with neomycin leads to a significant reduction in IBS symptoms, and the type of gas seen on LBT is also associated with IBS subgroup.
Updates on treatment of irritable bowel syndrome.
TLDR
A physiologically-based overview of recently developed and frequently employed pharmaceutical agents used to treat IBS is provided, and some non-pharmaceutical options that may be beneficial in this disorder are discussed.
Advances in the management of irritable bowel syndrome
TLDR
It is now widely accepted that the prevalence of IBS is between 10% and 20% of the US population and that the direct and indirect costs associated with IBS are significant.
Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report.
TLDR
Both the traditional binary and 50% improvement end points are equivalent in their psychometric properties, neither is impacted by baseline severity, and both demonstrate excellent construct validity.
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
TLDR
The data do not support an important role for SIBO according to commonly used clinical definitions, in irritable bowel syndrome, however, mildly increased counts of small-bowel bacteria seem to be more common in IBS, and needs further investigation.
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
TLDR
This monograph was developed to educate physicians about its epidemiology, diagnostic approach, and treatments of Irritable Bowel Syndrome to critically evaluate the rapidly expanding research about IBS.
...
...